ConversationStéphane BancelCEO & Director Good morning, good afternoon. Welcome to Moderna's headquarter. Thank you so much for taking the time today to be with us in person or to be with us online. So welcome to Moderna 2025 Analyst Day. As you know, our mission is really the North Star of this company. We want to work together with all our stakeholders to deliver the greatest possible impact to people through mRNA medicine. If you think about the near term, our strategy is really set up on two axes. One i ...

Moderna (NasdaqGS:MRNA) 2025 Analyst Day November 20, 2025 09:00 AM ET Company ParticipantsAmanda Sorrento - Head of HR CoreDarren Edwards - Program Leader for mRNA-1283Nathan Sauveur - Manager of HR Technical OperationsRaffael Nachbagauer - Head of Platform and Technology Integration and VP of DevelopmentNone - Company RepresentativeCraig Kennedy - Head of Global Supply ChainDan Culpdon - Senior Fellow leading Computational Design and In Vitro SelectionGerhard Eller - Senior Director of Global Logistics an ...

Moderna is to expand its US manufacturing capabilities with the onshoring of drug product manufacture to its existing Moderna Technology Center (MTC) in Norwood in the state of Massachusetts, in a move involving an investment of more than $140m. Through this onshoring, the company will now operate complete end-to-end mRNA medicines manufacturing across the country. It is expected to strengthen Moderna's network in the US, supporting commercial as well as clinical supply. The initiative forms part of the ...

Company Overview - Arcturus Therapeutics specializes in creating mRNA vaccines and therapies [3] Allegations and Impact - Edelson Lechtzin LLP is investigating potential violations of federal securities laws involving Arcturus, stemming from allegations of providing misleading business information to investors [1] - On October 22, 2025, Arcturus reported Phase 2 trial results for its inhaled mRNA therapy ARCT-032 in cystic fibrosis, which showed no meaningful improvement in lung function (FEV1) [4] - Following the trial results announcement, Arcturus's stock price dropped by 50.17%, closing at $11.54 per share [4]

Core Insights - Akeso, Inc. has initiated a Phase I clinical trial for its personalized mRNA vaccine AK154, targeting pancreatic cancer as both a monotherapy and in combination with bispecific antibodies cadonilimab and ivonescimab [1][2][4] Company Overview - Akeso is a leading biopharmaceutical company founded in 2012, focusing on innovative biological medicines and has developed a comprehensive end-to-end drug development platform [8] - The company has over 50 innovative assets in its pipeline, with 24 candidates currently in clinical trials, including 15 bispecific/multispecific antibodies [8] Product Development - AK154 is Akeso's first mRNA-based therapeutic candidate, designed to address the "cold tumor" phenotype in pancreatic cancer by utilizing sequence-specific mRNA vaccines [2][3] - Preclinical data for AK154 indicates strong immunogenicity and anti-tumor activity, suggesting a favorable safety profile when combined with Akeso's bispecific antibodies [4]

Core Insights - Moderna is a leading player in the biopharmaceutical industry, focusing on mRNA technology for vaccines and therapeutics across various disease categories [1] - The company has been recognized as a top employer for eleven consecutive years, reflecting its commitment to innovation and employee values [2] - In 2025, Moderna received approval for mNEXSPIKE, a new COVID-19 vaccine targeting specific age groups, supported by investments in advanced manufacturing [3] - The company emphasizes social responsibility through its charitable foundation and the integration of AI and robotics in its operations [4] - Despite recent achievements, Needham maintained a Hold rating for Moderna, with the stock price at $26.01 [5][6] Company Developments - Moderna's focus includes developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases [1] - The approval of mNEXSPIKE marks a significant milestone in expanding Moderna's product portfolio [3] - Investments in manufacturing hubs in Australia, Canada, and the UK enhance the company's pandemic readiness [3] Recognition and Ratings - The company has been recognized as a top employer in the biopharmaceutical industry for eleven consecutive years, highlighting its workplace culture [2][6] - Needham's Hold rating indicates a cautious outlook despite the company's ongoing developments and market interest [5][6] Social Responsibility and Innovation - Moderna's commitment to social responsibility is demonstrated through its charitable foundation and annual health impact report [4] - The integration of AI and robotics is aimed at driving innovation and creating a lasting impact in medicine [4]

The same Nobel-winning mRNA technology that helped curb the Covid-19 pandemic may be poised to transform cancer care https://t.co/mvsdbUVCNt ...

Core Viewpoint - BioNTech has initiated a public exchange offer for all outstanding shares of CureVac, aiming to combine their mRNA technologies to enhance cancer immunotherapy development [1][2]. Group 1: Acquisition Details - The acquisition is structured as an all-stock deal, with each CureVac share valued at approximately $5.46 in BioNTech American Depositary Shares (ADSs), leading to an implied total equity value of around $1.25 billion for CureVac [3]. - The exchange ratio is subject to a collar mechanism, adjusting based on the 10-day volume weighted average price (VWAP) of BioNTech ADSs, with specific ratios set for different price thresholds [3][7]. - The offer is set to expire on December 3, 2025, unless extended or terminated earlier, and requires at least 80% of CureVac's shares to be tendered [5][7]. Group 2: Strategic Objectives - The acquisition is intended to bolster BioNTech's capabilities in research, development, manufacturing, and commercialization of mRNA-based cancer immunotherapies, aligning with its oncology strategy [2][7]. - BioNTech's oncology strategy includes two main programs: mRNA-based cancer immunotherapy candidates and a bispecific antibody candidate, pumitamig (BNT327) [2]. Group 3: Shareholder Participation - CureVac shareholders wishing to participate in the offer are advised to contact their brokers or the information agent, Georgeson LLC, for further details [4][7]. - An extraordinary general meeting (EGM) for CureVac shareholders is scheduled for November 25, 2025, to vote on resolutions related to the transaction and corporate reorganization [8]. Group 4: Regulatory and Compliance - BioNTech has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) regarding the offer, which has not yet become effective [10]. - CureVac's management board recommends that shareholders tender their shares into the offer, as detailed in their filed solicitation/recommendation statement [10].

Core Insights - Moderna is transitioning to a new era, aiming to leverage its mRNA technology beyond COVID-19, with new vaccine approvals and a focus on cancer and artificial intelligence [2][4] - The company has faced significant challenges post-pandemic, with a notable decline in revenue and increased competition, raising questions about the sustainability of its recovery [2][3] Financial Performance - In the second quarter, Moderna reported total revenue of $142 million, a significant drop from pandemic highs, and a net loss of $825 million, although this was an improvement from a $1.3 billion loss a year prior [4] - The company has maintained strong cash and investment reserves of $7.5 billion, which provides a buffer as it navigates the post-COVID-19 landscape [5] - Operational expenses have been reduced by 40% year-over-year on a cash-cost basis, saving $581 million compared to the same period in 2024 [5] Product Development and Approvals - Moderna received three key FDA approvals this year, including mNEXSPIKE, mRESVIA for RSV, and full approval of Spikevax for children aged six months to 11 years, indicating progress in stabilizing its vaccine portfolio [6] - The company revealed promising Phase 3 data for its flu vaccine, which could lead to a flu-COVID-19 combination shot, enhancing its market position [7] - Moderna is expanding its non-respiratory vaccination and rare disease portfolios, and strengthening its oncology collaboration with Merck, focusing on customized neoantigen therapy [7]

Core Insights - The Moderna Innovation and Technology Centre (MITC) in Harwell, Oxfordshire is now fully operational, licensed to supply British-made COVID-19 vaccines to the UK population [1] - This facility is a key component of Moderna's ten-year strategic partnership with the UK Government, aimed at enhancing health resilience and promoting economic growth [1] - The MITC will produce mRNA respiratory vaccines for the UK public, supporting the National Health Service (NHS) seasonal vaccination programs [1]